Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12616001440415
Ethics application status
Approved
Date submitted
5/10/2016
Date registered
14/10/2016
Date last updated
4/08/2020
Date data sharing statement initially provided
19/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
There is no place like home.
Part 1. The Australian Predicting Infectious Complications in Children with Cancer (PICNICC) Project
Part 2. National Scale Up of the Low Risk Febrile Neutropenia Program
Scientific title
There is no place like home.
Part 1. The Australian Predicting Infectious Complications in Children with Cancer (PICNICC) Project
Part 2. National Scale Up of the Low Risk Febrile Neutropenia Program
Secondary ID [1] 289580 0
None
Universal Trial Number (UTN)
N/A
Trial acronym
PICNICC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Paediatric Cancer 299320 0
Febrile Neutropenia 299322 0
Microbiologically Documented Infection 299323 0
Sepsis 299324 0
Condition category
Condition code
Cancer 299311 299311 0 0
Children's - Brain
Cancer 299312 299312 0 0
Children's - Leukaemia & Lymphoma
Cancer 299313 299313 0 0
Children's - Other

Intervention/exposure
Study type
Observational
Patient registry
True
Target follow-up duration
30
Target follow-up type
Days
Description of intervention(s) / exposure
In part 1 of of this study, the aim is to prospectively validate nine clinical decision rules (CDRs) including the European-based PICNICC CDR, that stratify children with cancer and febrile neutropenia into low and high risk for microbiologically documented infection (MDI), so as to optimise their management and quality of life and improve resource allocation. The PICNICC CDR is based on five simple clinical variables including (i) tumour type (ii) maximum temperature, (iii) total white cell count, (iv) monocyte count, (v) haemoglobin and (vi) severity of illness. It provides the opportunity for a world first external validation of this globally derived rule and is a critical step before the rule can be safely implemented into practice.

In Part 1 and 2 of the study, patient demographic, FN episode and outcome data at day 0, completion of the FN episode and day 30 will be collected prospectively by the study-site research assistant/nurse (RA/RN) according to international consensus definitions. Patients that develop FN outside of RA/RN working hours will have relevant data collected retrospectively within 72 hours. Data will be entered into an electronic password protected study database (REDCap). Accuracy of data collection will be verified by project manager (first ten records for each site then periodically throughout recruitment) as well as chief investigator and site associate investigator.

For patient recruited only in part 1 of this study, novel biomarkers that predict outcomes will be identified using RNA sequencing (RNAseq) analysis on peripheral blood mononuclear cells (PBMC) collected from participants at Royal Children's Hospital Melbourne at two time points. Blood will be collected in EDTA tubes (5ml if <40kg and 12ml if >40kg). Peripheral blood samples will be processed by the Children’s Cancer Centre Tissue Bank. Within two hours of sample collection, plasma will be harvested following centrifugation and stored at -80 degrees celsius. PBMCs will be isolated by Ficoll density gradient centrifugation. PBMC will be cryopreserved and stored in the vapor phase of liquid nitrogen for in vitro assays and pelleted and resuspended in RNAlater for nucleic acid extraction. Samples will be batched and distributed by the CCC Tissue Bank.

RNAseq will be performed at MCRI (25-30 M coverage) on unstimulated and stimulated samples. Additionally PBMCs will be analysed by flow cytometry to determine the frequency of T cells, and monocytes. This latter data set will allow bioinformatic deconvolution to dissect the transcriptome of relevant cell types. When we have established which method (stimulated or unstimulated) provides that most robust data we will proceed to collect and analyses 100-200 samples . Flow cytometry and stimulation of PBMCs will be performed in the Pellegrini laboratory at the Walter and Eliza Hall Institute of Medical Research. The cell samples sent to WEHI will be thawed and placed in culture medium. During the pilot study these samples will be unstimulated or stimulated with agents that are known to amplify immune responses for a few hours. The medium the cells were kept in will then be collected, to be analysed upon completion of transcriptome analysis for secreted immunogenic factors. The cells themselves will be labelled with specific antibodies which will distinguish the individual cells into subtypes of immune cells and their activation status. During this process all the cells will be run on a machine to analyse composition. Therefore no cells will remain after the analysis has taken place. However, the culture medium these cells were kept in will be stored indefinitely at -80 degrees celsius in the secure Pellegrini laboratory freezer. RNA sequencing is being carried out to identify biomarkers that can predict the outcome of FN episodes only. The transcriptome analysis performed as part of this study is purely exploratory. None of the tests being performed are validated or accredited as diagnostics. Therefore no information will be revealed about disease-predisposing germline traits, heritable disorders or parental identity.

To investigate the cost of patient in hospital versus patients managed at home, all consented patients will be reviewed for their cost information using hospital costs records for inpatient data and outpatient costs via the Medicare consent form, completed at patient recruitment by the RA.

The optional quality of life surveys have been replicated into an electronic format for consented parents/guardians and patients older than three years, The age ranges for the CHU-9D assessment (7 to 18 years and a proxy version for patients aged 3 to 6 years) have been stipulated by the University of Sheffield and will be adhered to when implementing the questionnaire. The RA will implement each tool electronically prior to discharge, providing education on how to complete the surveys. To provide a comprehensive overview of the true impact of FN and unplanned hospital admission on the child. For patients that have been discharged home, the surveys will be distributed electronically, via RedCAP, to valid email address.

In part 2 of the study, we will be evaluating the implementation process and the clinical, quality of life and economic impact of the low risk FN program across 8 hospitals in Australia. The Consolidated Framework for Implementation Research (CIFR) will be used (https://cfirguide.org/) to guide implementation and evaluation. This will be completed as a survey by the healthcare professionals. In addition, each site will have regular focus group meetings to review implementation processes for each site. Outcomes from these meetings will be reported back to the central management team for their review and consideration.

In summary, low risk febrile neutropenia patients will continued to be recruited as per Part 1, with the same frequency/duration of participation. The focus for Part 2 of the study will be on the hospitals and healthcare professionals implementing the low risk febrile neutropenia program at their site. Furthermore, we will continue to obtain Medicare data from patients to evaluate cost of patients at home versus patients staying in hospital.
Intervention code [1] 295184 0
Diagnosis / Prognosis
Comparator / control treatment
No control group
Control group
Uncontrolled

Outcomes
Primary outcome [1] 298800 0
Prospectively validate the internationally derived PICNICC clinical decision rule that predicts microbiologically documented infection in children with cancer and febrile neutropenia. Patient demographic, FN episode and outcome data will be collected prospectively by the study-site research assistant (RA) and will follow international consensus definitions.
Timepoint [1] 298800 0
Each FN episode will include data from presentation until 30 days after the FN occurrence, The study will take place over five years, allowing FN episodes that occur during this time to be captured.
Primary outcome [2] 298801 0
To identify novel biomarkers that predict outcomes we will perform RNA sequencing (RNAseq) analysis on peripheral blood mononuclear cells (PBMC) collected from participants at RCH Melbourne at two time points (part 1 of the study only).
Timepoint [2] 298801 0
Sample collection: at presentation (Day 1, hour 0-4) and 24hrs later (Day 2). Pilot data analysis post collection of first 20 samples, approximately one month. Exploratory analysis once all data collected, approximately 18 months post study commencement (part 1 of the study only).
Secondary outcome [1] 325238 0
Costs will be measured for outpatient and inpatient health care service use. The site RA will collect actual inpatient costs of each FN episode including bed-days, medications and investigations. This information is accessible from hospital health information systems. Costs for outpatient service use, where relevant, will be captured by accessing Medicare records for medical and pharmaceutical services. 3 months prior to 9 months post FN episode.
Timepoint [1] 325238 0
Require 12 months of data relevant to the FN episode, three months prior and nine months post. This will be collected for the entire participant cohort and information extracted for the twelve months relevant to each participants episode.
Secondary outcome [2] 328208 0
All patients greater than three years of age enrolled in the validation study will be given the option to participate in the quality of life (QOL) assessment. To test patient QOL the Child Health Utility 9D (CHU9D, University of Sheffield) will be used. This tool is validated for use in children aged 7 to 18 years and will allow this age group to self-report. A proxy completion version will be used for children aged 3 to 6 years.
Timepoint [2] 328208 0
QoL surveys will be administered to Participants at Day 1, Day 7 and Day 30. A reminder email will be sent for those who are yet to complete the survey at Day 3, Day 10 and Day 35.
Secondary outcome [3] 328388 0
All parents/guardians of participants enrolled in the validation study will be given the option to participate in the QOL assessment. Parent/guardian QOL will be assessed using the Assessment for Quality of Life 6D (AQoL-6D) and the CarerQOL.
Timepoint [3] 328388 0
QoL surveys will be administered to Parents/Guardians at Day 1, Day 7 and Day 30. A reminder email will be sent for those who are yet to complete the survey at Day 3, Day 10 and Day 35.
Secondary outcome [4] 385280 0
Satisfaction of implementation and impact of an evidence-based paediatric low-risk FN program across Australian hospitals, assessed by study-specific questionnaire completed by health professionals at each site. This is a composite secondary outcome i.e. satisfaction of implementation and satisfaction of impact.
Timepoint [4] 385280 0
Questionnaires will be distributed to health professionals across all sites participating on the program at the commencement of the study at sites.

Continued implementation assessment will be carried out throughout the duration of the trial in quarterly periods.

Eligibility
Key inclusion criteria
1. Children (age less than or equal to 18 years)
2. Diagnosis of cancer or leukaemia and on active treatment
3. Diagnosis of fever (greater than or equal to 38 degrees celsius) in the setting of neutropenia (absolute neutrophil count less than 1.0 cells/microlitre)
Minimum age
No limit
Maximum age
18 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Febrile neutropenia treatment commenced at a non-participating site
2. Allogeneic haematopoietic stem cell transplant within preceding 3 months
3. Febrile neutropenia episode occurred while patient was receiving concurrent intravenous or oral antibiotics (excluding prophylaxis)

Study design
Purpose
Screening
Duration
Longitudinal
Selection
Defined population
Timing
Prospective
Statistical methods / analysis
International data indicate that microbiologically documented infection occurs in between 18 and 25% of episodes of febrile neutropenia. This is supported by local pilot data at Monash Children’s Hospital and Royal Children’s Hospital. For validation of the PICNICC clinical decision rule (Objective 1), 780 episodes of febrile neutropenia, with an estimated event rate of 18%, are required for 80% power to show AUC-ROC of the PICNICC model is greater than or equal to 0.7. Accounting for a 10% dropout the target for recruitment is 848 across the 8 study sites.

The sample size for the biomarker study (Objective 2) will be calculated from an exploratory study. The bioinformatics department at the Walter and Eliza Hall Institute (WEHI) will perform power calculations in the preliminary data to ascertain a sufficient sample size. Based on their experience 100-200 participants with 200-400 samples should provide adequate data for correlative analyses.

Quality of life (QoL) will be reported using the descriptive systems and as the mean utility values derived using the standard algorithms for each instrument (Objective 3). These will be reported for children, and their parents/guardians, with and without an MDI and those classified as high and low risk, and taking into account the impact of key demographic factors on QoL (such as age, gender, income and educational status). The implications of MDI for quality adjusted survival will be explored using modelling approach to combine the observed utility values with patient survival.

Economic data will be reported as total cost and the cost per day of admission and episodes with and without an MDI and those classified as high and low risk will be compared. Mean estimates of costs will be used and confidence intervals will be generated by boot-strapping the data. Results will be presented as a cost-consequence analysis in terms of the mean costs and quality of life effects (expressed as utility values) associated with and without an MDI event.

Implementation evaluation (Objective 4) will be an ongoing iterative process to identify any new barriers arise through the implementation process. Post implementation clinical, economic and QoL data for episodes identified as low risk will be compared to pre-implementation data from part of of this study and matched according to risk status. Continuous data will be presented as median and interquartile range. Mann–Whitney U test was used to estimate P-values for continuous data and Fisher’s exact test for categorical data. P-value <0.05 will be considered statistically significant. Qualitative data from post-implementation focus group meetings will be grouped according to theme and paired with corresponding solutions or changes to the program. Where appropriate, impact of individual changes will be done by comparing patient enrollment pre and post-program change.

The costs and outcomes for the low-risk FN program will be presented as a cost-consequence analysis to show the relative impact on costs and QoL outcomes of the two treatment programs (ie. hospital and home-based care). The data will also be combined in a modelled analysis to assess the average expected cost-effectiveness (cost per quality-adjusted-life-year) in patients with low-risk FN comparing hospital and home-based management. A modelled analysis will be used to account for the potential longer-term impacts on costs and outcomes of the alternatives approaches to low-risk FN management. Overall, confidence intervals around the costs and outcomes will be generated by bootstrapping the data, and the robustness of the analysis explored using sensitivity analysis.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
17/10/2016
Actual
31/10/2016
Date of last participant enrolment
Anticipated
30/11/2022
Actual
Date of last data collection
Anticipated
30/12/2022
Actual
Sample size
Target
1352
Accrual to date
858
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment hospital [1] 6056 0
The Royal Childrens Hospital - Parkville
Recruitment hospital [2] 6057 0
Monash Medical Centre - Clayton campus - Clayton
Recruitment hospital [3] 6059 0
John Hunter Children's Hospital - New Lambton
Recruitment hospital [4] 6060 0
Womens and Childrens Hospital - North Adelaide
Recruitment hospital [5] 6062 0
Sydney Children's Hospital - Randwick
Recruitment hospital [6] 6063 0
The Children's Hospital at Westmead - Westmead
Recruitment hospital [7] 6064 0
Princess Margaret Hospital - Subiaco
Recruitment hospital [8] 17190 0
Queensland Children's Hospital - South Brisbane
Recruitment hospital [9] 17191 0
Perth Children's Hospital - Nedlands
Recruitment postcode(s) [1] 13505 0
3052 - Parkville
Recruitment postcode(s) [2] 13506 0
3168 - Clayton
Recruitment postcode(s) [3] 13507 0
2145 - Westmead
Recruitment postcode(s) [4] 13508 0
2031 - Randwick
Recruitment postcode(s) [5] 13510 0
2305 - New Lambton Heights
Recruitment postcode(s) [6] 13512 0
5006 - North Adelaide
Recruitment postcode(s) [7] 13513 0
6008 - Subiaco
Recruitment postcode(s) [8] 30895 0
6009 - Nedlands

Funding & Sponsors
Funding source category [1] 293970 0
Government body
Name [1] 293970 0
National Health and Medical Research Council
Country [1] 293970 0
Australia
Funding source category [2] 306355 0
Government body
Name [2] 306355 0
Medical Research Future Fund
Country [2] 306355 0
Australia
Primary sponsor type
Hospital
Name
Peter MacCallum Cancer Centre
Address
305 Grattan Street
Melbourne VIC 3000
Country
Australia
Secondary sponsor category [1] 292783 0
Hospital
Name [1] 292783 0
The Royal Children's Hospital
Address [1] 292783 0
50 Flemington Road
Parkville VIC 3052
Country [1] 292783 0
Australia
Other collaborator category [1] 281412 0
Other
Name [1] 281412 0
Murdoch Children's Research Institute
Address [1] 281412 0
Royal Children's Hospital, 50 Flemington Rd, Parkville VIC 3052
Country [1] 281412 0
Australia
Other collaborator category [2] 281413 0
University
Name [2] 281413 0
University of Melbourne
Address [2] 281413 0
Parkville VIC 3010
Country [2] 281413 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 295385 0
The Royal Children's Hospital Human Research Ethics Committee
Ethics committee address [1] 295385 0
Ethics committee country [1] 295385 0
Australia
Date submitted for ethics approval [1] 295385 0
11/07/2016
Approval date [1] 295385 0
29/09/2016
Ethics approval number [1] 295385 0
HREC / 16 / RCHM / 108

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 67066 0
Dr Gabrielle M Haeusler
Address 67066 0
Peter MacCallum Cancer Institute
Department of Infectious Diseases
305 Grattan Street
Melbourne VIC 3000
Country 67066 0
Australia
Phone 67066 0
+61409237348
Fax 67066 0
Email 67066 0
Gabrielle.Haeusler@petermac.org
Contact person for public queries
Name 67067 0
Marijana Vanevski
Address 67067 0
Murdoch Children's Research Institute
50 Flemington Rd, Parkville, VIC, Australia, 3052
Country 67067 0
Australia
Phone 67067 0
+61 3 93456519
Fax 67067 0
Email 67067 0
Marijana.Vanevski@mcri.edu.au
Contact person for scientific queries
Name 67068 0
Gabrielle M Haeusler
Address 67068 0
Peter MacCallum Cancer Institute
Department of Infectious Diseases
305 Grattan Street
Melbourne VIC 3000
Country 67068 0
Australia
Phone 67068 0
+61409237348
Fax 67068 0
Email 67068 0
Gabrielle.Haeusler@petermac.org

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseExamining health-related quality of life in pediatric cancer patients with febrile neutropenia: Factors predicting poor recovery in children and their parents.2021https://dx.doi.org/10.1016/j.eclinm.2021.101095
EmbaseBlood transcriptomics identifies immune signatures indicative of infectious complications in childhood cancer patients with febrile neutropenia.2022https://dx.doi.org/10.1002/cti2.1383
EmbasePrevalence and predictors of poor outcome in children with febrile neutropaenia presenting to the emergency department.2022https://dx.doi.org/10.1111/1742-6723.13978
N.B. These documents automatically identified may not have been verified by the study sponsor.